Thieler Law Corp, member of the Investor Attorney Network, is investigating whether certain officers and directors of Rockwell Medical Inc (NASDAQ: RMTI) violated securities laws in connection with certain financial statements.

The investigation seeks to discover if possible claims on behalf of purchasers of the securities of Rockwell Medical Inc (NASDAQ: RMTI) concerning whether a series of statements by Rockwell Medical Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On September 9, 2015, Rockwell Medical Inc disclosed the U.S. commercial launch of Triferic, a FDA approved iron product designed to replace iron and preserve hemoglobin in hemodialysis patients in the United States. On February 29, 2016, Rockwell Medical's Chief Financial Officer Tom Klema disclosed to investors on a conference call that sales of Triferic were “immaterial” for 2015.

Following this news, NASDAQ: RMTI shares declined 37.5% during intraday trading on March 1, 2016.

Based in Wixom, Michigan, and founded in 1995 Rockwell Medical Inc operates as an integrated biopharmaceutical company.

If you purchased shares of Rockwell Medical Inc (NASDAQ: RMTI) on or before February 29, 2016, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185